Biogen Idec Inc BIIB:NASDAQ (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
360.67 6.97   1.97%3,691,3311.8M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Market is closed. As of 04:00 PM ET 12/19/2014

Latest News Headlines for Biogen Idec Inc

Biotech Equities Update - Biogen Idec, ACADIA Pharma, Halozyme Therapeutics, Neurocrine Biosciences, and Bluebird Bio

Editor Note: For more information about this release, please scroll to bottom. LONDON, December 12, 2014 /PRNewswire/ -- Investor-Edge has initiated coverage on the following equities: Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Halozyme Therapeutics Inc. (NASDAQ: HALO), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, December 11, 2014, the NASDAQ Composite ended at 4,708.16, up 0.52%, the Dow Jones Industrial Average advanced 0.36%, to finish the day at 17,596.34, and the S&P 500 closed at 2,035.33, up 0.45%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index also advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:

View more recent headlines

Peers Information HelpBIIB Biogen Idec Inc vs. Peers

BIIB
Biogen Idec Inc
26.51%
Johnson & Johnson
16.62%
Pfizer Inc.
4.37%
Merck & Co., Inc.
17.84%
AbbVie Inc
28.61%
BIIB
Biogen Idec Inc
0.00%
Johnson & Johnson
2.65%
Pfizer Inc.
3.51%
Merck & Co., Inc.
3.02%
AbbVie Inc
2.89%
BIIB
Biogen Idec Inc
1.97%
-1.18%
Johnson & Johnson
-0.09%
Pfizer Inc.
Merck & Co., Inc.
1.02%
-0.31%
AbbVie Inc
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

http://www.biogenidec.com/

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open343.28
Previous Close353.70
Day High361.93
Day Low343.06
52 Week HighToday | 361.93
52 Week Low1/6/2014 | 270.62
% Off 52 Week High(0.35)%
% Off 52 Week Low33.28%
Beta (5 Yr)1.10
Volatility Avg12/19/2014 | 35.57
10-Day Avg. Volume1,804,620
Market data is delayed by at least 20 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)9/30/2014 | 10.57
P/E Ratio9/30/2014 | 33.5
Market CapLarge Cap | 85.2B
Shares Outstanding236.16M
Float235.9M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short2.48M
Short Ratio1.6
Short % of Float1.05%
As of 11/28/2014